A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: Sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics

Clinical Drug Investigation

Volumn 30, Issue 8, 2010, Pages 517-531

  Morera Domínguez, Carles ^a   Ceberio Balda, Félix ^b   Flórez Garca, Mariano ^c   Masramón, Xavier ^d   López Gómez, Vanessa ^e  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b Rehabilitation Unit   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Back pain, treatment; Cost effectiveness; Pregabalin, therapeutic use

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DICLOFENAC; IBUPROFEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN; TRAMADOL; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

ABSENTEEISM; ADULT; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; COST CONSEQUENCE ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; ELECTROSTIMULATION THERAPY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYDROTHERAPY; INTERMETHOD COMPARISON; IONTOPHORESIS; LOW BACK PAIN; LOW LEVEL LASER THERAPY; MAGNETOTHERAPY; MAJOR CLINICAL STUDY; MALE; NERVE BLOCK; NEUROPATHIC PAIN; ORTHOPEDIC SURGERY; ORTHOSIS; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT CARE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RATING SCALE; REHABILITATION CENTER; SPINAL CORD STIMULATION; TRACTION THERAPY; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT RESPONSE; WORKING TIME; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; ECONOMICS; MIDDLE AGED;

ADULT; AGED; ANALGESICS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PROSPECTIVE STUDIES;

EID: 77954178301     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536280-000000000-00000     Document Type: Article

References (44)

1. Enthoven P, Skargren E, Carstensen J, et al. Predictive factors for 1-year and 5-year outcome for disability in a working population of patients with low back pain treated in primary care. Pain 2006; 122: 137-144
2. IASP Task Force in Taxonomy. Pain terms: a current list with definitions and notes on usage. In: Merksey H, Bogduk N, editors. Classification of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle (WA): IASP Press, 1994: 206-213
3. Dionne CE, Dunn KM, Croft PR, et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine 2008; 33: 95-103
4. Webb R, Brammah T, Lunt M, et al. Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UKgeneral population. Spine 2003; 28: 1195-1202
5. Loney PL, Stratford PW. The prevalence of low back pain in adults: a methodological review of the literature. Phys Ther 1999; 79: 384-396
6. Lachaine J, Gordon A, Choiniere M, et al. Painful neuropathic disorders: an analysis of the Regie de l'Assurance Maladie du Quebec database. Pain Res Manag 2007; 12 (1): 31-37
7. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006; 10: 127-135
8. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003; 25 (5 Suppl.): S12-7
9. Rodrguez MJ, Garca AJ. A registry of the aetiology and costs of neuropathic pain in pain clinics: results of the Registry of Etiologies and Costs (REC) in Neuropathic Pain Disorders study. Clin Drug Investig 2007; 27: 771-782
10. Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001; 344: 363-370
11. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007; 23: 15-22
12. Smith BH, Torrance N, Bennett MI, et al. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007; 23: 143-149
13. Galvez R, Rejas J, Perez M, et al. Prevalence of neuropathic pain in Spain: clinical, working and health care implications. Med Clin (Barc) 2005; 125: 221-229
14. Mason VL, Mathias B, Skevington SM. Accepting low back pain: is it related to a good quality of life? Clin J Pain 2008; 24: 22-29
15. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635
16. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305
17. Lopez-Trigo J, Sancho Rieger J. Pregabalin: a new treatment for neuropathic pain. Neurologia 2006; 21: 96-103
18. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454
19. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008; 136: 150-157
20. Freynhagen R, Grond S, Schupfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007; 61: 1989-1996
21. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain 2005; 115: 254-263
22. Gallagher RM. Naturalistic study designs in samples with refractory pain: advantages and limitations. Pain Med 2004; 5 (2): 143-145
23. Sackett D, Rosenberg W, Gray J, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-72
24. Morera-Domnguez C, Ceberio-Balda F, Florez-Garca M, et al. Healthcare and non-healthcare resources utilization and related costs in subjects with refractory pain associated to neck pain: a post-hoc analysis of the effect of pregabalin in a 12-week prospective study under routine medical practice conditions [abstract]. Value Health 2008; Suppl.: A637
25. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization, 1992
26. Bouhassira D, Attal N, Fermanian J, etal. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108: 248-257
27. Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathi-que 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007; 5: 66. doi:10.1186/1477-7525- 5-66 (Pubitemid 351188978)
28. Badia X, Muriel C, Gracia A, et al. Grupo VESBPI. Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain. Med Clin (Barc) 2003; 120: 52-59
29. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-370
30. Vilagut G, Ferrer M, Rajmil L, et al. The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gac Sanit 2005; 19: 135-150
31. Catalogo de Especialidades Farmaceuticas 2007. Consejo General de Colegios Oficiales de Farmaceuticos. Madrid: 2007 [online]. Available from URL: http://www.portalfarma.com/Home.nsf/Home?OpenForm [Accessed 2007 Dec 1]
32. Oblikue cost database year 2006. Oblikue Consulting 2007 [online] Available from URL: http://www.oblikue.com/bddcostes [Accessed 2007 Mar 1]
33. Instituto Nacional de Estad?stica (INE). Ministerio de Trabajo y Asuntos Sociales [online]. Available from URL: http://www.ine.es/daco/daco42/etcl/ etcl0206.pdf. [Accessed 2007 Jan 28]
34. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27: S178-89
35. Thompson SG, Barber JA. How should cost datainpragmatic randomised trials be analysed? BMJ 2000; 320: 1197-1200
36. Chiechio S, Zammataro M, Caraci F, et al. Pregabalin in the treatment of chronic pain: an overview. Clin Drug Investig 2009; 29: 203-213
37. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-638
38. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22-27
39. Gilron I, Bailey JM. Trends in opioid use for chronic neuropathic pain: a survey of patients pursuing enrollment in clinical trials. Can J Anaesth 2003; 50: 42-47
40. Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections: are they economically justifiable? Pharmaco-economics 2000; 18 (2): 95-104
41. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5 (3): 143-149
42. Garca AJ, Rodrguez MJ. Costes del dolor neuropatico segun etiolog?a en las Unidades del Dolor en Espana. Rev Soc Esp Dolor 2007; 6: 404-415
43. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8: 8-20
44. Asche CV, Kirkness CS, McAdam-Marx C, et al. The societal costs of low back pain: data published between 2001 and 2007. J Pain Palliat Care Pharmacother 2007; 21: 25-33